Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

HutchMed In-licenses Epigenetic Cancer Drug in $310 Million Deal

publication date: Aug 9, 2021

Shanghai's HutchMed announced a $310 million deal to acquire greater China rights to Epizyme's epigenetic treatment for niche cancers. Tazverik® is a methyltransferase inhibitor of EZH2 developed by Boston's Epizyme that is approved is the US to treat patients with epithelioid sarcoma or follicular lymphoma. HutchMed has not previously in-licensed any products. It will pay $25 million upfront and the rest in milestones. In addition, HutchMed will have a four-year warrant to acquire up to $65 million of Epizyme shares. More details....

Stock Symbols: (NSDQ/AIM: HCM; HKEX: 13) (NSDQ: EPZM)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here